Neoleukin Therapeutics General Counsel Holly Vance resigns

Neurogene Inc.

Holly Vance resigns as General Counsel and Corporate Secretary effective Nov 17, 2021 to pursue another opportunity.
Transition period under negotiation; Vance expected to provide consulting services as needed.
No replacement named; CFO Robert Ho signs the filing.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Holly Vance

General Counsel and Corporate Secretary

NGNE · Neurogene Inc.

Effective: 2021-11-17
Filed: November 19, 2021, 6:59 PM ET

On November 17, 2021, Neoleukin Therapeutics, Inc. (the “Company”) received notice from Holly Vance of her intention to resign as the Company’s General Counsel and Corporate Secretary to pursue another opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Holly Vance resigned as General Counsel and Corporate Secretary at Neurogene Inc..

Action: resigned
Role: General Counsel and Corporate Secretary

Exact text from the filing

On November 17, 2021, Neoleukin Therapeutics, Inc. (the “Company”) received notice from Holly Vance of her intention to resign as the Company’s General Counsel and Corporate Secretary to pursue another opportunity.

View on SEC.gov

Neurogene Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-334588

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.